Regenxbio (RGNX) Gross Profit (2014 - 2025)

Regenxbio's Gross Profit history runs 12 years deep, the most recent figure standing at $21.2 million for Q4 2025.

• On a quarterly basis, Gross Profit rose 42.45% year-over-year to $21.2 million in Q4 2025; TTM through Dec 2025 was $145.0 million, a 195.69% increase from a year earlier, with the FY2025 full-year figure at $136.0 million, up 173.24% from the prior year.
• Gross Profit eased to $21.2 million in Q4 2025 per RGNX's latest filing, from $24.0 million in the prior quarter.
• Across five years, Gross Profit topped out at $375.6 million in Q4 2021 and bottomed at $6.5 million in Q1 2022.
• The 5-year median for Gross Profit is $15.0 million (2023), against an average of $36.2 million.
• Across the five-year window, Gross Profit jumped 3257.14% in 2021 and plunged 95.06% in 2022, its largest moves.
• Year by year, Gross Profit stood at $375.6 million in 2021, then plunged by 95.06% to $18.6 million in 2022, then plunged by 40.87% to $11.0 million in 2023, then jumped by 35.73% to $14.9 million in 2024, then jumped by 42.45% to $21.2 million in 2025.
• Per Business Quant, the three latest RGNX Gross Profit figures stand at $21.2 million (Q4 2025), $24.0 million (Q3 2025), and $16.2 million (Q2 2025).